Catégorie : Actualités

Characterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence, Sam Craft et al., 2019

Characterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence Sam Craft, Adam Winstock, Jason Ferris, Clare Mackie, Michael T. Lynskey and Tom P. Freeman Psychological Medicine, 2019, 1–10. doi : 10.1017/S0033291719002460   Abstract Background. As new cannabis products and administration methods proliferate, patterns of use are becoming increasingly heterogeneous. However, few studies have explored different profiles of cannabis use and their association with problematic use. Methods. Latent class analysis (LCA) was used to identify subgroups of past-year cannabis users endorsing distinct patterns of use from a large international sample [...]

Lire la suite

Stroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes, R. DESAI, 2019

Stroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes DESAI R., SINGH S., PATEL K., GOVAL H., SHAH M., MANSURI Z., PATEL S., MAHUWALA Z.K., GOLDSTEIN L.B., QURESHI A.I. International Journal of Stroke, 2019, doi: 10.1177/1747493019895651 Abstract BACKGROUND : Recent legalization of therapeutic and recreational cannabis use makes it imperative to have an insight into odds and trends in young-onset stroke-related hospitalizations among cannabis users (18-49 years). METHODS : The National Inpatient Sample dataset (2007-2014) was utilized to assess national trends, odds of young-onset stroke-related hospitalizations, and outcomes among cannabis users vs. nonusers using provided discharge weights, strata, and cluster design. [...]

Lire la suite

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain, Esraa Aly et al.,

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106   Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]

Lire la suite

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice, Eva M. Schleicher et al., 2019

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094   The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]

Lire la suite

The European Congress on Legal and Regulations in Cannabis, Vienna, Austria,13-14 February 2020

The European Congress on Legal and Regulations in Cannabis Vienna, Austria 13-14 February 2020 Dear Colleagues, It is with great pleasure that we invite you to attend The European Congress on Legal and Regulations in Cannabis (LR-Cannabis) taking place 13-14 February 2020 in Vienna, Austria.   The Congress aim is to learn more about the requirements and processes of medical cannabis under the law and other regulations, as well as to present valuable professional knowledge.   READ MORE

Lire la suite

‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration, T.P. Freeman & V.Lorenzetti, 2019

'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]

Lire la suite

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements, Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements   Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020.   Le Cannabis comme anti-émétique :   Les prescriptions médicales, chez les adultes (THC naturel ou synthétique - Nabilone) comme chez les enfants (delta 8-THC, Abrahamov et al, 1995), ont débutées dès 1975. L’efficacité a été prouvée dans de nombreux essais cliniques, et de nombreuses méta-analyses (8/9 pour le cannabis et 3/3 pour le Nabilone, Penta et al, 1981). Par contre les effets psychotropiques peuvent être mal supportés par de nombreux patients, et justifie l’arrêt, ou la diminution des doses. Les associations variables THC/CBD présente un intérêt probable. Aucun effet indésirable persistant ou fatal [...]

Lire la suite

Are Your Patients Taking CBD? – Medscape – January 15, 2020

Are Your Patients Taking CBD? - Medscape - January 15, 2020 https://www.medscape.com/viewarticle/923801   Cannabidiol (CBD) is having its moment in the sun. A Gallup poll from last August found that 1 in 7 Americans use CBD, that 11% of users are 50 to 64 years of age, and that 8% are at least 65 years of age. Pain relief, anxiety, insomnia, and arthritis are the top reasons for use. Nearly 4 in 10 Americans think CBD oils should be legally available for adults to buy over the counter. Although the 2018 Farm Bill removed hemp (cannabis and cannabis derivatives such as CBD that contain less than 0.3% THC) [...]

Lire la suite

Cannabinoid Regulation of Fear and Anxiety : an Update, Eleni P. Papagianni & Carl W. Stevenson, 2019

Cannabinoid Regulation of Fear and Anxiety : an Update Eleni P. Papagianni & Carl W. Stevenson Current Psychiatry Reports, 2019, 21, 38 doi : 10.1007/s11920-019-1026-z   Abstract Purpose of Review : Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings : Evidence from preclinical studies has shown that the non-psychotropic phyto-cannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear [...]

Lire la suite